DrugPatentWatch Database Preview
Drugs in Development Information for Aminopterin
» See Plans and Pricing
What is the development status for investigational drug Aminopterin?
Aminopterin is an investigational drug.
There have been 106 clinical trials for Aminopterin.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2001.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Lymphoid, and Precursor Cell Lymphoblastic Leukemia-Lymphoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Children's Oncology Group, and Fred Hutchinson Cancer Research Center.
Summary for Aminopterin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 383 |
| WIPO Patent Applications | 389 |
| Japanese Patent Applications | 190 |
| Clinical Trial Progress | Phase 3 (2001-10-01) |
| Vendors | 35 |
Recent Clinical Trials for Aminopterin
| Title | Sponsor | Phase |
|---|---|---|
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | M.D. Anderson Cancer Center | Phase 1/Phase 2 |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | National Cancer Institute (NCI) | Phase 3 |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for Aminopterin
Top disease conditions for Aminopterin
Top clinical trial sponsors for Aminopterin
US Patents for Aminopterin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
